NY A10219

Requires insurance policies covering cancer treatment drugs to cover FDA-approved drugs prescribed off-label (for cancer types not FDA-approved) if recognized in specified reference compendia

Updates approved reference compendia from American Medical Association Drug Evaluations and United States Pharmacopeia Drug Information to include American Hospital Formulary Service-Drug Information, National Comprehensive Cancer Networks Drugs and Biologics Compendium, Thomson Micromedex Drugdex, and Elsevier Gold Standard's Clinical Pharmacology

Allows insurers to add other authoritative compendia as identified by the federal Secretary of Health and Human Services or Centers for Medicare & Medicaid Services

Excludes coverage requirements for experimental or investigational drugs and drugs the FDA has determined to be contraindicated for the specific cancer type being treated

Applies these requirements to individual health insurance policies, group and blanket policies, and medical expense indemnity corporations, hospital service corporations, and health service corporations; effective January 1 following enactment